Health effects of supplementation of carnosine and beta-alanine in the elderly population
Authors:
Česák Ondřej; Študent Vladimír jr.; Vidlář Aleš
Authors‘ workplace:
Urologická klinika LF UP a FN Olomouc
Published in:
Geriatrie a Gerontologie 2022, 11, č. 4: 171-175
Category:
Review Article
Overview
Globally, the population is ageing. Healthcare should prepare for this situation and look for ways to improve, prolong and improve the quality of life of the ageing population. Ageing is associated with changes in physiological functions, such as changes in skeletal muscle activity, loss of muscle mass and reduced strength, changes in bone tissue and a decline in sensory and cognitive functions.
Deterioration of the human body in old age may be associated with reduced tissue concentrations of carnosine, whereby the protection of cell membranes from oxidative damage is reduced. It seems that by consuming foods rich in carnosine or by enriching the diet with β-alanine, these degenerative processes could be slowed down.
The amino acid β-alanine is one of the world‘s most widely used sports supplements to improve exercise performance because it is a precursor of carnosine, which is important for striated muscle function. This paper aims to report on supplementation with β-alanine, a precursor of carnosine, which represents one of the few proven dietary interventions that could help not only in the fight against aging and muscle loss, but also in the prevention of other diseases such as senile cataracts, neurodegenerative diseases and peripheral artery and vein disease.
Keywords:
sarcopenia – Peripheral vascular disease – cataract – Beta-alanine – carnosine – cognitive funtions
Sources
1. United Nations. World Population Ageing 2013. Tech Rep 2013; (United Nations, Department of Economic and Social Affairs, Population Division).
2. Dolan E, Swinton PA, Painelli V de S, et al. A Systematic Risk Assessment and Meta-Analysis on the Use of Oral β-Alanine Supplementation. Adv Nutr 2019; 10(3): 452–463.
3. Gulewitsch W, Amiradžibi S. Ueber das Carnosin, eine neue organische Base des Fleischextractes. Berichte der Dtsch Chem Gesellschaft 1900; 33(2): 1902–1903.
4. Xing L, Chee ME, Zhang H, et al. Carnosine—a natural bioactive dipeptide: bioaccessibility, bioavailability and health benefits. J Food Bioact 2019; 5: 8–17.
5. Chmielewska K, Dzierzbicka K, Inkielewicz-Stępniak I, Przybyłowska M. Therapeutic Potential of Carnosine and Its Derivatives in the Treatment of Human Diseases. Chem Res Toxicol 2020; 33(7): 1561–1578.
6. Peters V, Jansen EEW, Jakobs C, et al. Anserine inhibits carnosine degradation but in human serum carnosinase (CN1) is not correlated with histidine dipeptide concentration. Clin Chim Acta 2011; 412(3-4): 263–267.
7. Stuerenburg HJ. The roles of carnosine in aging of skeletal muscle and in neuromuscular diseases. Biochemistry (Mosc) 2000; 65(7): 862–865.
8. Hipkiss AR. Would Carnosine or a Carnivorous Diet Help Suppress Aging and Associated Pathologies? Ann N Y Acad Sci 2006; 1067(1): 369–374.
9. Hipkiss AR. Glycation, ageing and carnosine: Are carnivorous diets beneficial? Mech Ageing Dev 2005; 126(10): 1034–1039.
10. Artioli GG, Sale C, Jones RL. Carnosine in health and disease. Eur J Sport Sci 2019; 19(1): 30–39.
11. Boldyrev AA, Dupin AM, Pindel EV, Severin SE. Antioxidative properties of histidine-containing dipeptides from skeletal muscles of vertebrates. Comp Biochem Physiol Part B Comp Biochem 1988; 89(2): 245–250.
12. Nicoletti VG, Santoro AM, Grasso G, et al. Carnosine interaction with nitric oxide and astroglial cell protection. J Neurosci Res 2007; 85(10): 2239–2245.
13. Corona C, Frazzini V, Silvestri E, et al. Effects of Dietary Supplementation of Carnosine on Mitochondrial Dysfunction, Amyloid Pathology, and Cognitive Deficits in 3xTg-AD Mice. Feany M, ed. PLoS One 2011; 6(3): e17971.
14. Dolan E, Saunders B, Dantas WS, et al. A Comparative Study of Hummingbirds and Chickens Provides Mechanistic Insight on the Histidine Containing Dipeptide Role in Skeletal Muscle Metabolism. Sci Rep 2018; 8(1): 14788.
15. Boldyrev AA, Aldini G, Derave W. Physiology and Pathophysiology of Carnosine. Physiol Rev 2013; 93(4): 1803–1845.
16. Holliday R, McFarland GA. A role for carnosine in cellular maintenance. Biochemistry (Mosc) 2000; 65(7): 843–848.
17. Villari V, Attanasio F, Micali N. Control of the Structural Stability of α-Crystallin under Thermal and Chemical Stress: The Role of Carnosine. J Phys Chem B 2014; 118(47): 13770–13776.
18. Nagai K, Suda T. [Immunoregulative effects of carnosine and betaalanine]. Nihon Seirigaku Zasshi 1986; 48(6): 564–571.
19. Yang Q-J, Zhao J-R, Hao J, et al. Serum and urine metabolomics study reveals a distinct diagnostic model for cancer cachexia. J Cachexia Sarcopenia Muscle 2018; 9(1): 71–85.
20. Hipkiss AR, Baye E, de Courten B. Carnosine and the processes of ageing. Maturitas 2016; 93: 28–33.
21. del Favero S, Roschel H, Solis MY, et al. Beta-alanine (CarnosynTM) supplementation in elderly subjects (60–80 years): effects on muscle carnosine content and physical capacity. Amino Acids 2012; 43(1): 49–56.
22. Culbertson JY, Kreider RB, Greenwood M, Cooke M. Effects of Beta- Alanine on Muscle Carnosine and Exercise Performance: A Review of the Current Literature. Nutrients 2010; 2(1): 75–98.
23. McCormack WP, Stout JR, Emerson NS, et al. Oral nutritional supplement fortified with beta-alanine improves physical working capacity in older adults: A randomized, placebo-controlled study. Exp Gerontol 2013; 48(9): 933–939.
24. Sampson UKA, Fowkes FGR, Mc- Dermott MM, et al. Global and Regional Burden of Death and Disability From Peripheral Artery Disease: 21 World Regions, 1990 to 2010. Glob Heart 2014; 9(1): 145.
25. Brevetti G, Silvestro A, Di Giacomo S, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg 2003; 38(2): 374–379.
26. Feehan J, Hariharan R, Buckenham T, et al. Carnosine as a potential therapeutic for the management of peripheral vascular disease. Nutr Metab Cardiovasc Dis. Published online July 2022.
27. Kawahara M, Tanaka K, Kato- Negishi M. Zinc, Carnosine, and Neurodegenerative Diseases. Nutrients 2018; 10(2): 147.
28. Takeuchi K, Toyohara H, Sakaguchi M. A hyperosmotic stress-induced mRNA of carp cell encodes Na+- and Cl− dependent high affinity taurine transporter1The sequence reported in this paper has been deposited in the DDBJ/ EMBL/GenBank database with accession no. AB006986.1. Biochim Biophys Acta - Biomembr 2000; 1464(2): 219–230.
29. Hisatsune T, Kaneko J, Kurashige H, et al. Effect of Anserine/Carnosine Supplementation on Verbal Episodic Memory in Elderly People. Asada T, ed. J Alzheimer’s Dis 2015; 50(1): 149–159.
30. Rokicki J, Li L, Imabayashi E, et al. Daily Carnosine and Anserine Supplementation Alters Verbal Episodic Memory and Resting State Network Connectivity in Healthy Elderly Adults. Front Aging Neurosci 2015; 7.
31. Schön M, Mousa A, Berk M, et al. The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence. Nutrients 2019; 11(6): 1196.
32. Baraniuk JN, El-Amin S, Corey R, et al. Carnosine Treatment for Gulf War Illness: A Randomized Controlled Trial. Glob J Health Sci 2013; 5(3).
33. Lawton G. Review of The measurement of adult intelligence. Am J Orthopsychiatry 1939; 9(4): 808–810.
34. Antonio Molina J, Javier Jiménez- Jiménez F, Gómez P, et al. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson’s disease. J Neurol Sci 1997; 150(2): 123–127.
35. Ghanbari HA, Ghanbari K, Harris PLR, et al. Oxidative damage in cultured human olfactory neurons from Alzheimer’s disease patients. Aging Cell 2004; 3(1): 41–44.
36. Fonteh AN, Harrington RJ, Tsai A, et al. Free amino acid and dipeptide changes in the body fluids from Alzheimer’s disease subjects. Amino Acids 2007; 32(2): 213–224.
37. Boldyrev A, Fedorova T, Stepanova M, et al. Carnisone Increases Efficiency of DOPA Therapy of Parkinson’s Disease: A Pilot Study. Rejuvenation Res 2008; 11(4): 821–827.
38. Lindfield R, Vishwanath K, Ngounou F, Khanna R. The challenges in improving outcome of cataract surgery in low and middle income countries. Indian J Ophthalmol 2012; 60(5): 464.
39. Abdelkader H, Longman M, Alany RG, Pierscionek B. On the Anticataractogenic Effects of LCarnosine: Is It Best Described as an Antioxidant, Metal-Chelating Agent or Glycation Inhibitor? Oxid Med Cell Longev 2016; 2016: 1–11.
40. Wang AM, Ma C, Xie ZH, Shen F. Use of carnosine as a natural antisenescence drug for human beings. Biochemistry (Mosc) 2000; 65(7): 869–871.
41. Babizhayev MA, Deyev AI, Yermakova VN, et al. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 2001; 22(6): 979–994.
42. Dubois VD-P, Bastawrous A. Nacetylcarnosine (NAC) drops for age-related cataract. Cochrane Database Syst Rev 2017; 2017(2).
43. Bae ON, Serfozo K, Baek SH, et al. Safety and Efficacy Evaluation of Carnosine, an Endogenous Neuroprotective Agent for Ischemic Stroke. Stroke 2013; 44(1): 205– 212.
Labels
Geriatrics General practitioner for adults Orthopaedic prostheticsArticle was published in
Geriatrics and Gerontology
2022 Issue 4
Most read in this issue
- A Pilot Study of the Mini-Cog Czech version in Czech Adults
- Opioid analgesics in the pain management of geriatric patients
- Vybrané faktory prevence u seniorů
- The association between diabetes mellitus 2 and geriatric syndromes – the results of international studies